PL2484352T3 - Płynne kompozycje octanu wapnia - Google Patents

Płynne kompozycje octanu wapnia

Info

Publication number
PL2484352T3
PL2484352T3 PL11192965T PL11192965T PL2484352T3 PL 2484352 T3 PL2484352 T3 PL 2484352T3 PL 11192965 T PL11192965 T PL 11192965T PL 11192965 T PL11192965 T PL 11192965T PL 2484352 T3 PL2484352 T3 PL 2484352T3
Authority
PL
Poland
Prior art keywords
calcium acetate
liquid compositions
individual
sweetener
administering
Prior art date
Application number
PL11192965T
Other languages
English (en)
Inventor
Stephen C Tarallo
Original Assignee
Lyne Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38957385&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2484352(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lyne Laboratories Inc filed Critical Lyne Laboratories Inc
Publication of PL2484352T3 publication Critical patent/PL2484352T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
PL11192965T 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia PL2484352T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83209306P 2006-07-21 2006-07-21
EP07836163A EP2048948B1 (en) 2006-07-21 2007-07-20 Liquid compositions of calcium acetate
EP11192965.9A EP2484352B1 (en) 2006-07-21 2007-07-20 Liquid compositions of calcium acetate

Publications (1)

Publication Number Publication Date
PL2484352T3 true PL2484352T3 (pl) 2014-12-31

Family

ID=38957385

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11192965T PL2484352T3 (pl) 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia
PL07836163T PL2048948T3 (pl) 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07836163T PL2048948T3 (pl) 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia

Country Status (18)

Country Link
US (3) US8591938B2 (pl)
EP (2) EP2048948B1 (pl)
JP (1) JP5335674B2 (pl)
KR (1) KR101553719B1 (pl)
CN (2) CN104095838A (pl)
AT (1) ATE547099T1 (pl)
AU (1) AU2007275606B9 (pl)
BR (1) BRPI0714882A2 (pl)
CA (1) CA2658465C (pl)
ES (1) ES2382993T3 (pl)
HK (2) HK1129814A1 (pl)
IL (1) IL196584A0 (pl)
MX (1) MX2009000722A (pl)
NZ (1) NZ574331A (pl)
PL (2) PL2484352T3 (pl)
RU (1) RU2463060C2 (pl)
WO (1) WO2008011126A2 (pl)
ZA (1) ZA200900472B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012627A2 (en) * 2004-07-23 2006-02-02 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
JP5261187B2 (ja) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
EP2048948B1 (en) 2006-07-21 2012-02-29 Lyne Laboratories, Inc. Liquid compositions of calcium acetate
EA035911B1 (ru) * 2006-12-18 2020-08-31 Акселерон Фарма Инк. Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI480048B (zh) * 2007-02-01 2015-04-11 Acceleron Pharma Inc 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TWI548647B (zh) * 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN104548056B (zh) * 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
CN107412734A (zh) * 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
NZ602471A (en) * 2008-06-26 2014-10-31 Acceleron Pharma Inc Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ590327A (en) * 2008-06-26 2013-12-20 Acceleron Pharma Inc Methods for dosing an activin-actriia antagonist and monitoring of treated patients
PT3494986T (pt) 2008-08-14 2020-07-14 Acceleron Pharma Inc Armadilhas para gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
KR20120028358A (ko) 2009-06-12 2012-03-22 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
KR20120062874A (ko) * 2009-09-09 2012-06-14 악셀레론 파마 인코포레이티드 ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도
AU2010315245B2 (en) * 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP2501400B1 (en) * 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP5766021B2 (ja) * 2010-05-14 2015-08-19 興和株式会社 安定な水性液剤
EP2441436A1 (de) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
BE1019709A3 (fr) * 2010-12-22 2012-10-02 Calxx Laboratoires S A Produit alimentaire organo-mineral et procede de preparation.
US9149529B2 (en) * 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
PT3227675T (pt) 2014-12-03 2023-05-30 Celgene Corp Antagonistas da ativina-actrii e utilizações para tratamento da síndrome mielodisplásica
CN104688681B (zh) * 2015-03-17 2018-01-02 常州康普药业有限公司 利巴韦林口服液及其制备方法
JP6718212B2 (ja) * 2015-08-17 2020-07-08 三菱商事ライフサイエンス株式会社 酢酸カルシウムのえぐ味抑制方法
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
WO2020150460A1 (en) * 2019-01-18 2020-07-23 Milne Iii Donald A Micronized aspirin formulation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093710A (en) * 1976-07-07 1978-06-06 Sandoz, Inc. Rapid dissolving effervescent granules
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
JPS6136222A (ja) * 1984-07-26 1986-02-20 Chugai Pharmaceut Co Ltd 高リン酸血症治療剤
GB8629781D0 (en) 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US4870105B1 (en) 1987-04-07 1998-03-10 Braintree Lab Phosphorus binder
CN1067250A (zh) 1991-05-28 1992-12-23 北京师范大学 桐酸系间苯二酚甲醛树脂的合成方法
DE19528524C2 (de) 1995-08-03 1999-11-11 Hans Dietl Calciumhaltiges Mittel zur intestinalen Phosphatbindung und Verfahren zu seiner Herstellung
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US5833954A (en) * 1996-08-20 1998-11-10 American Dental Association Health Foundation Anti-carious chewing gums, candies, gels, toothpastes and dentifrices
CN1162489A (zh) 1997-02-25 1997-10-22 青岛盖宝特保健品有限公司 酪磷肽钙营养液
CN1067250C (zh) 1997-08-21 2001-06-20 中国人民解放军总装备部后勤部军事医学研究所 中性补钙制剂
US5976507A (en) 1998-06-04 1999-11-02 Colgate Palmolive Company Dentrifice composition containing encapsulated reactive ingredients
US5858333A (en) 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
DE19917705C1 (de) 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
CN1242963A (zh) 1999-07-26 2000-02-02 李久成 补钙可乐及其制备方法
CN1252278A (zh) 1999-09-16 2000-05-10 冯荣根 锌钙海狸营养品
JP2001204440A (ja) * 2000-01-25 2001-07-31 Mitsukan Group Honsha:Kk カルシウム飲料
WO2002011716A2 (en) 2000-08-07 2002-02-14 Ranbaxy Signature Llc Liquid formulation of metformin
CN1159993C (zh) 2000-10-26 2004-08-04 李久成 一种强化多元素离子饮料及其制备方法
US6576665B2 (en) 2001-04-03 2003-06-10 Braintree Laboratories, Inc. Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
US20030026872A1 (en) * 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
CN1520284A (zh) 2001-05-29 2004-08-11 波切夫斯特鲁姆基督教高等教育大学 包含乙酸钙的厌食组合物
JP2002363105A (ja) * 2001-05-31 2002-12-18 Taiho Yakuhin Kogyo Kk 不快な味のマスキング方法及び内服用液剤
ITMI20011284A1 (it) 2001-06-19 2002-12-19 Salvatore Bilardello Composizione farmaceutica per il trattamento dell'iperfosfatemia
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
GB2395124A (en) 2002-11-16 2004-05-19 Fluid Technologies Plc Palatable microcapsules
MXPA05005335A (es) 2002-11-22 2005-07-25 Firmenich & Cie Composiciones orales las cuales enmascaran el sabor salado de las sales.
EP1755578B2 (en) 2004-06-01 2018-11-28 Takeda AS Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
GB2416981A (en) 2004-08-13 2006-02-15 Nutraceuticals Ltd Premixes, flour enriched with same, mineral supplemented foodstuffs and methods of manufacture therefore.
US7862836B2 (en) * 2005-04-12 2011-01-04 Biolink Life Sciences, Inc. Phosphorus binder for treatment of kidney disease
EP2048948B1 (en) 2006-07-21 2012-02-29 Lyne Laboratories, Inc. Liquid compositions of calcium acetate

Also Published As

Publication number Publication date
KR20090040340A (ko) 2009-04-23
HK1202815A1 (en) 2015-10-09
JP5335674B2 (ja) 2013-11-06
CA2658465A1 (en) 2008-01-24
CN101522021B (zh) 2014-07-30
US8592480B2 (en) 2013-11-26
MX2009000722A (es) 2009-06-11
BRPI0714882A2 (pt) 2013-05-21
US20080021104A1 (en) 2008-01-24
EP2484352A1 (en) 2012-08-08
EP2048948B1 (en) 2012-02-29
IL196584A0 (en) 2009-11-18
US20140255515A1 (en) 2014-09-11
ES2382993T3 (es) 2012-06-15
US20110251282A1 (en) 2011-10-13
RU2009104774A (ru) 2010-08-20
CA2658465C (en) 2016-06-14
HK1129814A1 (en) 2009-12-11
EP2048948A4 (en) 2009-11-11
JP2009544615A (ja) 2009-12-17
KR101553719B1 (ko) 2015-09-16
CN101522021A (zh) 2009-09-02
ZA200900472B (en) 2009-11-25
CN104095838A (zh) 2014-10-15
WO2008011126A3 (en) 2008-09-18
WO2008011126A2 (en) 2008-01-24
NZ574331A (en) 2011-01-28
US8591938B2 (en) 2013-11-26
AU2007275606A1 (en) 2008-01-24
PL2048948T3 (pl) 2012-07-31
EP2048948A2 (en) 2009-04-22
AU2007275606B9 (en) 2013-09-26
AU2007275606B2 (en) 2013-06-06
RU2463060C2 (ru) 2012-10-10
EP2484352B1 (en) 2014-07-09
US9089528B2 (en) 2015-07-28
ATE547099T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
HK1202815A1 (en) Liquid compositions of calcium acetate
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007117778A3 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
IL195030A (en) IV dpp inhibitor assemblies
WO2007052023A3 (en) Novel compounds
TW200612892A (en) Novel compounds
WO2008013838A3 (en) Pyridizinone derivatives
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
TW200630336A (en) Novel compounds
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
TW200745003A (en) Novel compounds
WO2007135241A3 (en) Composition and method for binding acetaldehyde in stomach
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2009100275A3 (en) Compositions and devices
WO2007130821A3 (en) Mglur5 modulators ii
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2008033935A3 (en) Vinorelbine derivatives
WO2007104933A8 (en) Chemical compounds
WO2008098143A3 (en) Antimicrobial compounds and methods of use
MY147271A (en) Accelerating agent of calcium absorption
WO2009043577A3 (de) 19-nor-progesterone zur kontrazeption
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2007089315A3 (en) Chewing gum composition including free, unencapsulated neotame and encapsulated high-intensity sweetener